Ind-Swift Laboratories Limited

INDSWFTLAB.BO

INDSWFTLAB.BOInd-Swift Laboratories Limited IN flag

Bombay Stock Exchange

107.80

INR

-2.05

(-1.87%)

60.74EPS

1.77P/E

6.53BMarket Cap

Aug 11Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

INE915B01019

Return %

Stock

S&P500

-8.95

9.99

19.16

59.68

19.16

94.43

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	392.85	289.79	235.6	161.23	159.47	168.31	169.19	161.81	157.62	150.85	175.8	204.33	216.78	75.95
Basic EPS, GAAP	24.86	-30.07	-29.79	-29.14	-14.33	-9.2	4.88	6.19	-4.28	-0.53	-0.36	8.06	71.24	60.13
Free Cash Flow per Basic Share	-48.26	-25.74	8.44	14.44	10.71	14.91	11.52	-17.07	23.06	22.09	22.32	30.78	-35.14	- -
Dividend per Share	0.95	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	102.66	64.14	32.02	3.06	-11.18	-11.89	-6.22	-0.74	-2.87	-2.78	-3.09	5.16	76.28	- -
Tangible Book Value per Share	154.7	146.05	111.77	84.03	70.52	76.31	92.59	109.43	121.22	100.53	101.52	115.41	157.64	- -
Basic Weighted Avg Shares	36	39	41	41	41	43	45	47	49	59	59	59	59	59
Sales/Revenue/Turnover	14,092	11,361	9,651	6,605	6,532	7,162	7,625	7,566	7,796	8,913	10,387	12,073	12,809	4,471
Operating Margin (%)	10.5	1.82	0.21	3.85	5.11	4.82	8.11	5.89	9.38	12.45	8.9	15.04	16.79	9.21
Depreciation Expense	399	544	658	843	847	883	866	1,040	901	873	1,310	574	533	134
Net Income, GAAP	892	-1,179	-1,220	-1,194	-587	-391	220	289	-212	-31	-21	476	4,210	3,540
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	38.93	41.73	- -	117.48	117.15	44.72	27.56	27.39
Profit Margin (%)	6.33	-10.38	-12.64	-18.07	-8.98	-5.46	2.88	3.83	-2.72	-0.35	-0.21	3.94	32.86	79.17
Working Capital	3,668	3,603	3,589	870	-1,454	-1,733	-976	4,801	5,400	6,297	7,409	7,934	4,399	- -
LT Debt	7,110	8,182	9,644	8,161	6,842	5,920	5,205	9,656	8,913	8,846	8,483	7,531	112	- -
Total Equity	8,237	8,534	7,252	5,945	5,174	5,313	5,490	5,878	6,406	6,034	6,009	6,819	9,314	- -
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	2.39	1.66	- -	-1.18	-1	6.42	11.9	- -
Return on Capital (%)	- -	- -	- -	- -	- -	- -	3.85	7.99	- -	-1.94	-1.85	10.44	66.88	-120.66
Return on Common Equity (%)	43.23	-38.05	-63.78	-166.16	- -	- -	- -	- -	- -	- -	- -	- -	174.96	- -

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	3.89%	11.25%	6.1%
Net Income, GAAP	-203.12%	-364.09%	784.44%
Free Cash Flow	-58.57%	-80.74%	-214.18%
Total Cash Common Dividend	- -	- -	- -
Total Equity	3.49%	10.57%	36.59%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Navrattan R. Munjal
Full Time Employees: 47
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: Shivalik Enclave Manimajra India 160101
Website: indswiftlabs.com
Similar Companies: Crescita Therapeutics Inc. (CTX.TO)
CV Sciences, Inc. (CVSI)
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ)
BioGaia AB (publ) (BIOG-B.ST)
Cannabis Strategic Ventures (NUGS)
Cannabis Global, Inc. (CBGL)
Business: Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, and antineoplastic, as well as various products for ADHD symptoms. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company also exports its products. The company was incorporated in 1995 and is headquartered in Manimajra, India.

	Jun'25	Sep'25	Dec'25
ST Debt	- -	55	- -
LT Borrowings	- -	109	- -
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	- -	59	- -
Market Capitalization	7,657	7,639	6,458

	Jun'25	Sep'25	Dec'25
Total Current Assets	- -	5,868	- -
Accounts Receivable, Net	- -	575	- -
Cash, Cash Equivalents & STI	- -	4,385	- -
Inventories	- -	93	- -
Total Current Liabilities	- -	1,644	- -
Payables & Accruals	- -	- -	- -
ST Debt	- -	55	- -
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	3.36	4.29	4.65	- -	8.06
2024	2.92	5.36	3.29	- -	71.24
2025	0.16	0.07	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	- -	- -	- -	- -	- -
2024	- -	- -	- -	- -	- -
2025	- -	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	2,802	3,102	3,127	3,042	12,073
2024	3,103	2,897	2,875	3,933	12,809
2025	332	120	87	- -	- -

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	392.85	289.79	235.6	161.23	159.47	168.31	169.19	161.81	157.62	150.85	175.8	204.33	216.78	75.95
Basic EPS, GAAP	24.86	-30.07	-29.79	-29.14	-14.33	-9.2	4.88	6.19	-4.28	-0.53	-0.36	8.06	71.24	60.13
Free Cash Flow per Basic Share	-48.26	-25.74	8.44	14.44	10.71	14.91	11.52	-17.07	23.06	22.09	22.32	30.78	-35.14	- -
Dividend per Share	0.95	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	102.66	64.14	32.02	3.06	-11.18	-11.89	-6.22	-0.74	-2.87	-2.78	-3.09	5.16	76.28	- -
Tangible Book Value per Share	154.7	146.05	111.77	84.03	70.52	76.31	92.59	109.43	121.22	100.53	101.52	115.41	157.64	- -
Basic Weighted Avg Shares	36	39	41	41	41	43	45	47	49	59	59	59	59	59
Sales/Revenue/Turnover	14,092	11,361	9,651	6,605	6,532	7,162	7,625	7,566	7,796	8,913	10,387	12,073	12,809	4,471
Operating Margin (%)	10.5	1.82	0.21	3.85	5.11	4.82	8.11	5.89	9.38	12.45	8.9	15.04	16.79	9.21
Depreciation Expense	399	544	658	843	847	883	866	1,040	901	873	1,310	574	533	134
Net Income, GAAP	892	-1,179	-1,220	-1,194	-587	-391	220	289	-212	-31	-21	476	4,210	3,540
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	38.93	41.73	- -	117.48	117.15	44.72	27.56	27.39
Profit Margin (%)	6.33	-10.38	-12.64	-18.07	-8.98	-5.46	2.88	3.83	-2.72	-0.35	-0.21	3.94	32.86	79.17
Working Capital	3,668	3,603	3,589	870	-1,454	-1,733	-976	4,801	5,400	6,297	7,409	7,934	4,399	- -
LT Debt	7,110	8,182	9,644	8,161	6,842	5,920	5,205	9,656	8,913	8,846	8,483	7,531	112	- -
Total Equity	8,237	8,534	7,252	5,945	5,174	5,313	5,490	5,878	6,406	6,034	6,009	6,819	9,314	- -
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	2.39	1.66	- -	-1.18	-1	6.42	11.9	- -
Return on Capital (%)	- -	- -	- -	- -	- -	- -	3.85	7.99	- -	-1.94	-1.85	10.44	66.88	-120.66
Return on Common Equity (%)	43.23	-38.05	-63.78	-166.16	- -	- -	- -	- -	- -	- -	- -	- -	174.96	- -

Ind-Swift Laboratories Limited

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year